Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 1953-1959, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mathis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mathis, G.

Clinical Chemistry, Vol 39, 1953-1959, Copyright © 1993 by American Association for Clinical Chemistry

Rare earth cryptates and homogeneous fluoroimmunoassays with human sera

G Mathis
Cis Bio International, Laboratoire des Produits pour l'Analyse Medicale, Bagnols sur Ceze, France.

The rare earth cryptates are used as long-lived fluorescent labels. They are formed by inclusion of a europium ion in the intramolecular cavity of a macropolycyclic ligand containing bipyridine groups as light absorbers. The use of fluoride ions in the measuring medium allows a total shielding of the label fluorescence. Here, I have established the conditions under which the signal of these cryptates can be amplified through the use of nonradiative energy transfer, and applied these conditions to homogeneous immunoassays by using allophycocyanin as the acceptor. Because only a low proportion of the cryptate label is involved in the transfer amplification, and because allophycocyanin emission occurs between the europium emission lines, time-resolved measurement of europium and allophycocyanin emission allows real-time correction of the optical properties of the assay medium. These features have allowed the development of a rapid homogeneous immunoassay of prolactin that can detect as little as 0.3 microgram/L (3rd International Standard 84/500).


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Lipid Res.Home page
S. Pandit, D. Wisniewski, J. C. Santoro, S. Ha, V. Ramakrishnan, R. M. Cubbon, R. T. Cummings, S. D. Wright, C. P. Sparrow, A. Sitlani, et al.
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
J. Lipid Res., June 1, 2008; 49(6): 1333 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Sarkissian, P. Fergelot, P.-J. Lamy, J.-J. Patard, S. Culine, P. Jouin, N. Rioux-Leclercq, and B. Darbouret
Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis
Clin. Chem., March 1, 2008; 54(3): 574 - 581.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. S. Fisher, P. L. Surdo, S. Pandit, M. Mattu, J. C. Santoro, D. Wisniewski, R. T. Cummings, A. Calzetta, R. M. Cubbon, P. A. Fischer, et al.
Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation
J. Biol. Chem., July 13, 2007; 282(28): 20502 - 20512.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
B. K. Hoefelschweiger, L. Pfeifer, and O. S. Wolfbeis
Screening Scheme Based on Measurement of Fluorescence Lifetime in the Nanosecond Domain
J Biomol Screen, October 1, 2005; 10(7): 687 - 694.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
J. R. Lakowicz, J. Malicka, E. Matveeva, I. Gryczynski, and Z. Gryczynski
Plasmonic Technology: Novel Approach to Ultrasensitive Immunoassays
Clin. Chem., October 1, 2005; 51(10): 1914 - 1922.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
A. Pommereau, E. Pap, and A. Kannt
Two Simple and Generic Antibody-Independent Kinase Assays: Comparison of a Bioluminescent and a Microfluidic Assay Format
J Biomol Screen, August 1, 2004; 9(5): 409 - 416.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
Q.-P. Qin, O. Peltola, and K. Pettersson
Time-resolved Fluorescence Resonance Energy Transfer Assay for Point-of-Care Testing of Urinary Albumin
Clin. Chem., July 1, 2003; 49(7): 1105 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
J. Karvinen, P. Hurskainen, S. Gopalakrishnan, D. Burns, U. Warrior, and I. Hemmila
Homogeneous Time-Resolved Fluorescence Quenching Assay (LANCE) for Caspase-3
J Biomol Screen, June 1, 2002; 7(3): 223 - 231.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
M. Preaudat, J. Ouled-Diaf, B. Alpha-Bazin, G. Mathis, T. Mitsugi, Y. Aono, K. Takahashi, and H. Takemoto
A Homogeneous Caspase-3 Activity Assay Using HTRF(R) Technology
J Biomol Screen, June 1, 2002; 7(3): 267 - 274.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
K. Spencer
Point-of-Care Screening for Chromosomal Anomalies in the First Trimester of Pregnancy
Clin. Chem., March 1, 2002; 48(3): 403 - 404.
[Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Lopez-Crapez, H. Bazin, E. Andre, J. Noletti, J. Grenier, and G. Mathis
A homogeneous europium cryptate-based assay for the diagnosis of mutations by time-resolved fluorescence resonance energy transfer
Nucleic Acids Res., July 15, 2001; 29(14): e70 - e70.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Soukka, J. Paukkunen, H. Harma, S. Lonnberg, H. Lindroos, and T. Lovgren
Supersensitive Time-resolved Immunofluorometric Assay of Free Prostate-specific Antigen with Nanoparticle Label Technology
Clin. Chem., July 1, 2001; 47(7): 1269 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
M. D. Boisclair, C. McClure, S. Josiah, S. Glass, S. Bottomley, S. Kamerkar, and I. Hemmila
Development of a Ubiquitin Transfer Assay for High Throughput Screening by Fluorescence Resonance Energy Transfer
J Biomol Screen, October 1, 2000; 5(5): 319 - 328.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
K. Enomoto, Y. Aono, T. Mitsugi, K. Takahashi, R. Suzuki, M. Preaudat, G. Mathis, G. Kominami, and H. Takemoto
High Throughput Screening for Human Interferon-y Production Inhibitor Using Homogenous Time-Resolved Fluorescence
J Biomol Screen, August 1, 2000; 5(4): 263 - 268.
[Abstract] [PDF]

Home page
 BloodHome page
B. Cassinat, P. Guardiola, S. Chevret, M.-H. Schlageter, M.-E. Toubert, J.-D. Rain, and E. Gluckman
Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia
Blood, August 1, 2000; 96(3): 859 - 863.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
A. J. Pope
Introduction LANCETM vs. HTRF(R) Technologies (or Vice Versa)
J Biomol Screen, December 1, 1999; 4(6): 301 - 302.
[PDF]

Home page
 J Biomol ScreenHome page
I. Hemmila
LANCETM: Homogeneous Assay Platform for HTS
J Biomol Screen, December 1, 1999; 4(6): 303 - 307.
[PDF]

Home page
 J Biomol ScreenHome page
G. Mathis
HTRF(R) Technology
J Biomol Screen, December 1, 1999; 4(6): 309 - 313.
[PDF]

Home page
 Mol. Endocrinol.Home page
G. Zhou, R. Cummings, Y. Li, S. Mitra, H. A. Wilkinson, A. Elbrecht, J. D. Hermes, J. M. Schaeffer, R. G. Smith, and D. E. Moller
Nuclear Receptors Have Distinct Affinities for Coactivators: Characterization by Fluorescence Resonance Energy Transfer
Mol. Endocrinol., October 1, 1998; 12(10): 1594 - 1604.
[Abstract] [Full Text]

Home page
 J Biomol ScreenHome page
J. Major
Challenges and Opportunities in High Throughput Screening: Implications for New Technologies
J Biomol Screen, February 1, 1998; 3(1): 13 - 17.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
J. M. Kolb, G. Yamanaka, and S. P. Manly
Use of a Novel Homogeneous Fluorescent Technology in High Throughput Screening
J Biomol Screen, June 1, 1996; 1(4): 203 - 210.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.